Australia markets open in 7 hours 57 minutes

Clarus Therapeutics Holdings, Inc. (CRXT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.22-0.50 (-8.74%)
As of 10:02AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close5.72
Open5.37
Bid5.26 x 1400
Ask5.29 x 900
Day's range5.17 - 5.37
52-week range3.43 - 31.24
Volume307,884
Avg. volume2,727,161
Market cap113.409M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-26.02
Earnings date18 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.80
  • GlobeNewswire

    Clarus Therapeutics Announces Issuance of Two New Patents for JATENZO® (testosterone undecanoate)

    JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions Clarus plans to list these patents in FDA’s Orange Book, which would bring the total number of Orange Book-listed patents covering JATENZO to seven NORTHBROOK, Ill., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to

  • GlobeNewswire

    Clarus Therapeutics Reports Third Quarter 2021 Financial and Operating Results

    Third quarter 2021 revenue increased 93% year-over-year to $4.3 million Third quarter 2021 total prescription growth for JATENZO® increased 12% sequentially and 132% year-over-year Conference call and webcast today at 5:15 p.m. ET NORTHBROOK, Ill., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today report

  • GlobeNewswire

    Clarus Therapeutics to Report Third Quarter 2021 Financial and Operating Results

    NORTHBROOK, Ill., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its third quarter 2021 financial and operating results on Thursday, November 18, 2021, after the market closes. Clarus will host a conference call on Thursday, November 18, 2021, at 5:15 p.m. ET to discuss the